GAMMA Investing LLC Invests $184,000 in Becton, Dickinson and Company (NYSE:BDX)

GAMMA Investing LLC purchased a new position in Becton, Dickinson and Company (NYSE:BDX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 772 shares of the medical instruments supplier’s stock, valued at approximately $184,000.

A number of other large investors also recently modified their holdings of BDX. Parkside Financial Bank & Trust increased its holdings in shares of Becton, Dickinson and Company by 26.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,190 shares of the medical instruments supplier’s stock worth $290,000 after acquiring an additional 250 shares during the period. SlateStone Wealth LLC increased its holdings in shares of Becton, Dickinson and Company by 10.6% in the 4th quarter. SlateStone Wealth LLC now owns 14,339 shares of the medical instruments supplier’s stock worth $3,496,000 after acquiring an additional 1,375 shares during the period. Marks Group Wealth Management Inc increased its holdings in shares of Becton, Dickinson and Company by 1.3% in the 4th quarter. Marks Group Wealth Management Inc now owns 26,396 shares of the medical instruments supplier’s stock worth $6,436,000 after acquiring an additional 334 shares during the period. RWA Wealth Partners LLC increased its holdings in shares of Becton, Dickinson and Company by 123.6% in the 4th quarter. RWA Wealth Partners LLC now owns 16,381 shares of the medical instruments supplier’s stock worth $3,994,000 after acquiring an additional 9,054 shares during the period. Finally, Jennison Associates LLC increased its holdings in shares of Becton, Dickinson and Company by 0.9% in the 4th quarter. Jennison Associates LLC now owns 383,564 shares of the medical instruments supplier’s stock worth $93,524,000 after acquiring an additional 3,287 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Up 0.5 %

BDX stock opened at $231.55 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The firm’s 50-day moving average is $239.24 and its two-hundred day moving average is $241.42. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The company has a market capitalization of $66.89 billion, a price-to-earnings ratio of 54.87, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. During the same period in the previous year, the firm earned $2.98 EPS. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. On average, analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BDX shares. Raymond James increased their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays increased their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.